Download presentation
Presentation is loading. Please wait.
Published byMonica Price Modified over 5 years ago
1
Association of the Expression of Mutant Epidermal Growth Factor Receptor Protein as Determined with Mutation-Specific Antibodies in Non-small Cell Lung Cancer with Progression-Free Survival after Gefitinib Treatment Koichi Azuma, MD, PhD, Isamu Okamoto, MD, PhD, Akihiko Kawahara, PhD, Tomoki Taira, PhD, Kazutaka Nakashima, PhD, Satoshi Hattori, PhD, Takashi Kinoshita, MD, PhD, Masayuki Takeda, MD, PhD, Kazuhiko Nakagawa, MD, PhD, Shinzo Takamori, MD, PhD, Michihiko Kuwano, MD, PhD, Mayumi Ono, PhD, Masayoshi Kage, MD, PhD Journal of Thoracic Oncology Volume 7, Issue 1, Pages (January 2012) DOI: /JTO.0b013e31822eeba2 Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions
2
FIGURE 1 Immunohistochemical staining of NSCLC adenocarcinoma specimens with antibodies specific for delE746-A750 or L858R mutant forms of EGFR. Representative staining patterns for each of the four intensity levels are shown (original magnification, ×400). Journal of Thoracic Oncology 2012 7, DOI: ( /JTO.0b013e31822eeba2) Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions
3
FIGURE 2 Kaplan-Meier survival curves according to expression score for EGFR mutants. PFS (A) and OS (B) for patients with high or low expression scores for either type of EGFR mutant. PFS for patients with high or low expression scores for exon 19 deletion (C) or L858R (D) mutant forms of EGFR. Journal of Thoracic Oncology 2012 7, DOI: ( /JTO.0b013e31822eeba2) Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions
Similar presentations
© 2024 SlidePlayer.com. Inc.
All rights reserved.